 |
||||
 |
Best Viewed on IE 7 |
|||
 |
 |
|||
 |
||||
      |
||||
|
In
the Spotlight .......................................................................................................................................................... Tyrosine Phosphatase SHP2 Promotes Breast Cancer Progression and Maintains Tumor-initiating Cells Many signaling networks are subverted at the biochemical level in cancer; new cancer therapies are likely to arise from an in-depth understanding of the signaling networks influencing tumor initiation, progression, and metastasis. Abnormal tyrosine phosphorylation underlies various diseases of deregulated growth and differentiation, including cancer. The first identified protein-tyrosine phosphatase (PTP) proto-oncogene was the Src-homology 2 domain-containing phosphatase, SHP2, encoded by PTPN11.
Tumor of the Month - Acute Lymphocytic Leukemia ..........................................................................................................................................................
Acute Lymphocytic Leukemias (ALLs),
which arise from immature lymphocytes in the bone marrow, are
the most common leukemias in children and the least common in
adults.1
The American Cancer Society estimates that there will be 6,050
new cases of ALL diagnosed in 2012 and 1,440 people will die
from the disease in the US alone.2
Risk of ALL has a bimodal distribution as children younger than
5 years are at the greatest risk of developing ALL. Risk
decreases after 20 years of age, and increases again after the
age of 50 years. The resulting lifetime risk of ALL is 1 in 800.3
Despite an increased risk, patients younger than 15 years have
the best prognosis: the 5-year survival is ~89%; whereas
adolescents between 15 and 19 years of age have a 5-year
survival of ~50%. Adults account for 80% of the
deaths due to ALL. A study published in the May issue of the
British Journal of Haematology attempts to discern why the
prognosis is much worse in older patients.4
One hundred ALL patients aged 55–65 years were compared with
1,814 patients aged 14–54 years, with the goal of understanding
why the outcome is much worse for older patients.
.......................................................................................................................................................... |
||||
|
|
||||
|
|
||||
|
The E-newsletter team: Dr. Shirish Kumar, Sarika Manchanda, Dr. Vinamrata Bhatia, Kimberly Scata, Monica Tuli.
Copyright©2012 SMARTANALYST Inc. All rights reserved CLICK HERE unsubscribe from the list CLICK HERE for previous issues
|
At SMARTANALYST, we support the decision-making process for licensing, business development, new product planning, and R&D groups within pharmaceutical and biotech companies. We currently work with leading pharmaceutical and biotech firms globally. | |||
